Thank you for submitting your manuscript for consideration by The EMBO Journal. We have now received the comments of three expert referees in the field, which you will find copied below. While the referees appreciate the method and findings as potentially interesting and valuable to the field, they however raise a number of major reservations regarding both the bioinformatics analysis and the functional validation in the case of the ALIX-V domain. It is also apparent that decisively addressing these points would require substantial further experimental efforts, and it is not fully clear whether this could be achieved within a limited revision period of maximally three months, on which we would have to insist in this case given the pending publication of competing manuscripts elsewhere. While you may therefore be best advised to seek rapid publication without major changes at another journal, I would nevertheless be willing to give you an opportunity to revise the manuscript for The EMBO Journal, in light of the current interest in the topic and the potential applicability of your methods. Such a revision could however only be considered under certain essential preconditions:
-the value of the prediction method will have to be substantially backed up along the lines requested by referee 1 (points B1-3) and referee 2 (point 1), as this is in my opinion the major and unique selling point of the study -in this line, we would have to insist on inclusion of the whole list of identified hits as requested by referee 1, point B1 -both in order to allow a better assessment of the method, and to make the study a really valuable resource to the field [I do recall that you are already conducting follow-up work on some of the identified hits, but I feel that this should not preclude their inclusion in the tables presented in the current study -they do not necessarily need to be discussed, and their inclusion here should certainly not pre-empt future publications of follow up studies] -furthermore, the question of correct contact residue prediction, and the issue of surface vs fold recognition raised by referee 1 will need to be thoroughly addressed -the validation work on ALIX-V needs to be substantially strengthened, ideally to identify a more decisive structure/bioinfo-predicted mutation that would abolish binding (see referee 1) , and to provide more decisive affinity measurements (as requested by all three referees) -the relevant ALIX experiments need to be repeated with the presence of potentially confounding GST tags (see referees 2, 3) -ALIX oligomerization will have to be confirmed by more suitable methods such as analytical ultracentrifugation, size exclusion chromatography etc -finally, the manuscript would be greatly strengthened by testing ALIX-V binding also to the two main types of poly/oligo-ubiquitin linked via K63 or K48
Should you be able to improve these key aspects of the study, as well as to satisfactorily clarify the various other specific points listed by the reviewers, then we should be able to consider the manuscript further for publication; but I have to make clear that we can only allow a single round of revision with a limited time frame in this special situation. Therefore, should you require any additional clarification here, please do not hesitate to contact me beforehand. I would also appreciate if you kept us updated about the status of the competing manuscripts. Please note that it is our policy that competing papers that appear while your work is formally under revision at our journal will have no negative impact on the final re-evaluation of your work.
Thank you again for the opportunity to consider this work for publication in our journal, and I look forward to hearing from you.
REFEREE REPORTS:
Referee #1 (Remarks to the Author):
The authors present a new bioinformatical method that aims to predict ubiquitin-binding surfaces in solved high-resolution structures (as collected in PDB), even if the structure does not contain ubiquitin and the surface residues have no homology to other UBDs. As a proof-of-principle, they predict a ubiquitin interface in the V-domain of the ALIX protein.
If the prediction method works as advertised, this would constitute a major progress worth publication in a high-impact journal, as it would allow the recognition of regulatory ubiquitinbinding domains even in one-off cases that are not members of large UBD super-families. The example picked in this manuscript, ALIX, had been implied in ubiquitin binding before. Thus, the crucial aspect of the experimental validation work is i) the proof that ALIX binds *directly* to ubiquitin and ii) that it does so via the contact residues predicted by the bioinformatical method. The authors provide several lines of evidence for substantiating these claims. Unfortunely, none of the results is really satisfactory.
Major points Bioinformatics: 1) Two runs of the prediction method (starting from the GAT:Ub and VHS:Ub contacs) are described and appear to yield valuable results, since several of the top-200 matches constitute known, non-trivial UBDs (i.e. not closely related to the seed-UBDs). Only selected database hits are shown in tables 1 and 2; the missing results most likely represent known or expected false-positives (structures that are unlikely to recognize ubiquitin). This lack of documentation is unfortunate, since it precludes a real assessment of the method, e.g. through uncovering general trends like preferring helical structures.
2) It is also unfortunate that for the 'true positive' hits (known or expected UBDs), no information on the predicted contact surfaces is given. If I understand the approach correctly, it should not just rank the PDB structures by ubiquitin-binding propensity, but also indicate on what predicted contact residues this score is based on. It should be easy to check to what extent the contact residues of the known UBDs have been predicted correctly.
3) Particularly problematic is the finding of multiple recognition partners for ubiquitin-like modifiers -especially if the authors' explanation is correct that those hits are based on the general fold similarity between ubiquitin and Sumo (in the case of Ubc9), Atg8 (in the case of Atg4A and Atg4B) or the UBX domain (in the case of p97 N-domain). At first glance, the fold-similarity might be an attractive explanation. However, the bioinformatical prediction method is based on the contact residues (of GAT or VHS) while binding to the Ile-44 patch of ubiquitin. However, the ubiquitinlike folds of Sumo, Atg8 and UBX do not contain this Ile-44 hydrophobic surface patch and are recognized completely differently. If the prediction method works ad advertised, it is hard to explain why those non-Ub recognition factors score that high (unless they contain a cryptic ubiquitinbinding surface?). In these cases, it would be of particular importance to know the predicted contact residues of the database hit and to check if those residues are involved in the recognition of the ubiquitin-fold partner.
Major points Validation:
1) There is little doubt that ALIX is involved in ubiquitin-mediated processes. The crucial task for the authors is to prove that the ALIX:Ub binding is direct and uses the residues predicted from bioinformatics. The authors do see an interaction between (bacterially expressed) ALIX-V and ubiquitin by pulling down ALIX-V with Ub-Agarose beads. The authors admit that pulling down ubiquitin by immobilized ALIX-V did not work, which could have a harmless explanation but could also mean that ALIX-V is an unspecifically sticky protein. Two mutations in bioinformatically predicted crucial contact residues reduces the pulldown efficiency to about 50% (Fig 5 A, B) . Double mutants used in the affinity measurement (see below) have apparently not been tested for pulldown. The 50% reduction is not really impressive; if I am not mistaken, most bona fide UBDs can be inactivated by mutating one or two key residues.
2) The measurement of the ALIX-V:Ub affinity was first perfomed by SPR and yielded a Kd of 2mM, which is unconvincing even by UBD standards. The authors then turned to microscale thermophoresis (MST) and found a Kd of 119 uM, which is in the acceptable range for a UBD. I must admit to not being familiar with the reliablity of MST measurements, but would have liked to see some explanation why the SPR results are considered to be wrong. The affinity of Ubrecognition is reduced to 320 uM and 461uM by mutating one or two key contact residues, respectivly. As in the pulldown experiments, the difference between wildtype and mutants are not impressive and I am not sure that they really support the claim of having (bioinformatically) identified the correct ubiquitin binding surface. The affinity is completely lost in a triple mutant, but the authors admit that this mutant has structural problems and don't use it in the follow-up experiments. What is really missing is a single or double mutant in bioinformatically predicted contact residues, which selectively loses its ubiquitin-binding while maintaining all other ALIX-V functions.
3) Dimerization of ALIX-V is discussed as one mechanism why immobilized Alix-V does not pull down ubiquitin. However, it is not clear how the claimed ALIX-V:Ub interaction mode, which is totally dependent on the Ile-44 patch, could be helped by dimerizing ALIX -given that the interaction partner is a single ubiquitin-unit, not a chain. The manuscript does not include any data on a possible preference for ubiquitin-chain recognition by ALIX-V. Nowadays, most UBDs are tested for binding to Mono-Ub and at least K48-and K63-linked ubiquitin chains. Strictly speaking, determination of chain specificity is not crucial for the validation of the bioinformatical claims. However, given the mixed results from the validation experiments, data on ubiquitin chain binding could be useful nevertheless. 4) Some of the observed problems in mutating away the ubiquitin affinity could be caused by the presence of a 2nd ubiquitin binding site in ALIX-V. This possibility is briefly mentioned in the manuscript but not followed-up on. Is the bioinformatical method capable of predicting secondary binding surfaces?
Minor points:
1) The authors state that most ubiquitin receptors are regulated by auto-ubiquitylation and that some of these processes are E3-independent. Unless the protein of interested is itself an E3, every autoubiquitylation must be E3-independent by definition.
2) Why is the MST measurement performed on GST-Alix? As far as I can see, GST is not required for the MST method and could interfere with the affinity.
3) The personal communication cited on page 13 was probably by Ron Kopito (rather than Kapito) 4) The manuscript does not discuss the evolutionary conservation of the predicted contact residues in ALIX. On the basis of conservation, it should be possible to predict if only human ALIX is predicted to bind ubiquitin or if this property is shared by ALIX proteins from differenc species.
Despite the major points of criticism, the data presented make it more likely than not that ALIX-V binds to ubiquitin, that this binding has physiological consequences, and that it uses the predicted interaction surface (possibly in combination with other surfaces). It is just the single, unequivocal proof for a direct binding (as bioinformatically predicted), which is missing.
Referee #2 (Remarks to the Author):
Keren-Kaplan et al. use existing structures in the PDB and the SiteEngine algorithm to predict possible ubiquitin-binding domains. This manuscript focuses on the ALIX-V domain, which has been previously shown to interact with ubiquitin in a pull-down experiment. They present a structural model and affinity measurements for the ALIX-V:ubiquitin complex, which is partially validated by site-directed mutagenesis as well as evidence that ALIX-V can be ubiquitylated without an E3 enzyme. Aspects of the manuscript seem premature however and some experiments may be over-interpreted, as detailed below.
1. The principle that ubiquitin complexes can be used to predict additional UBDs is reasonable and worth demonstrating. It is not clear however how the current work expands the already existing SiteEngine algorithm. Furthermore, if advancements have been made it is also not clear how the new software will be disseminated and more importantly, additional validation should be performed and comparisons made to currently existing approaches, including the currently available SiteEngine server. Figure 2 is clear from the text, but the figure itself is not obvious and does not contribute much. In addition the mutational analysis for Figure 5A is subtle at best and it is not clear whether the mutations made in Figure 5D compromise the structural integrity of ALIX. This is most likely the case for the ALIX-V triple mutant, and it is not clear whether the more soluble double mutant is properly folded. Overall this analysis does not convincing validate the structural model of Figure 3A . It is also not clear that the authors mean by "It is worth noting that large variability was found in the pulldown assays" (p. 8, top). T681A is not included in Figure 5 , but appears in the functional assay of Figure 7 . Finally, the concern of structural integrity of the ALIX-V double mutant becomes important for Figure 7 , as the authors specifically attribute effects to loss of Ub interaction. Also, ALIX-V mediated inhibition of WT EIAV Gag appears comparable to YPDL-Ub EIAV Gag by the E449A-I450S mutation, which is not how the data is presented in the text. The significant difference seems to be restricted to F676D.
The comparison intended in
3. Figure 4B should be also performed with reducing agent to validate the identification of ALIX~Ub.
4. The conclusion that ubiquitin stabilizes oligomeric ALIX is premature. The amount of oligomerized ALIX in Figure 6B and 6C with Ub present is tiny compared to the momeric species and although there is more oligomer with Ub than without, there is also less monomeric Alix shown in the lane marked -Ub. This section should be complemented with another technique such as analytical ultracentrifugation. In addition, it appears that the experiments of Fig 6 are being done without GST, but this point should be clarified as GST dimerizes.
Referee #3 (Remarks to the Author):
Kaplan and colleagues use an interesting computational approach here to identify new ubiquitin (Ub) binding domains (UBDs). The protein they focus on is Alix, which had previously been shown to bind ubiquitin-agarose, although those experiments were carried out with complex cell lysates and the interaction might have been indirect.
Alix is an interesting scaffold protein that is capable of linking up cargoes containing a YPLD motif, e.g. several retroviral matrix proteins to the ESCRT-III complex.
Based on their homology modelling efforts, the authors propose a possible structural model, which they partially test by introducing a number of mutations.
Whilst reporting on an interesting observation, and introducing an attractive approach to identify novel UBDs, the manuscript fails on several levels:
1. Whilst acknowledging in the discussion that the relevant ligand may well be K63-linked Ub chains, the only measurements provided in this paper are based on monomeric ubiquitin. If ubiquitin binding is promoting oligomerisation, assessing the effect of Ub chains would be highly relevant.
2. Figure 5B . It is disconcerting that the authors report their pulldown experiments as very variable and fail to provide error bars. In addition, they come up with extremely low affinity measurements using SPR, which are clearly at least 2-4 x lower than those reported for other UBD. One key issue with all binding experiments may be the use of GST-tagged proteins given that GST is known to promote parallel dimerisation. Clearly this can grossly confuse the issue in experiments aimed at measuring binding affinities and multimerisation, making some of the experiments hard to interpret (see eg Sims, NSMB 2009).
4. Figure 6A : The data used to derive the Hill coefficient (which in the abstract is erroneously given in µM), should be presented as a Hill plot. It is hard to see the single data points in the current graphs, but one wonders whether there are in fact enough data points in the critical region to confidently derive a Hill coefficient.
5. The functional data are based on an artificial Ub-cargo, rather than on a wild-type viral protein, and the assay measures the negation of a dominant negative inhibitory effect caused by overexpression of the Alix V-domain. In the end the assay simply measures ubiquitin binding again -but in a different context, rather than providing evidence for a physiological relevance or a requirement for Ub binding in endogenous Alix, which may be achieved by a knockdown and rescue experiment, with a viral gag protein that has not been fused to Ub.
6. The oligomerisation data based on crosslinking are very hard to interpret -could this be addressed by gel filtration? And is the protein used in these experiments also GST-tagged? The authors mention a potential second ubiquitin binding site -would that affect the multimerisation assays? Would these not better be conducted with the isolated V-domain? 
As you will see below we addressed all referees comments. We feel that these comments significantly improved the manuscript and it is now ready for publication in The EMBO J.
-we would have to insist on a resubmission time frame of 10 (or at the very most 12) weeks from now, without additional extensions -the value of the prediction method will have to be substantially backed up along the lines requested by referee 1 (points B1-3) and referee 2 (point 1), as this is in my opinion the major and unique selling point of the study -in this line, we would have to insist on inclusion of the whole list of identified hits as requested by referee 1, point B1 -both in order to allow a better assessment of the method, and to make the study a really valuable resource to the field [I do recall that you are already conducting follow-up work on some of the identified hits, but I feel that this should not preclude their inclusion in the tables presented in the current study -they do not necessarily need to be discussed, and their inclusion here should certainly not pre-empt future publications of follow up studies] -furthermore, the question of correct contact residue prediction, and the issue of surface vs fold recognition raised by referee 1 will need to be thoroughly addressed -the validation work on ALIX-V needs to be substantially strengthened, ideally to identify a more decisive structure/bioinfo-predicted mutation that would abolish binding (see referee 1), and to provide more decisive affinity measurements (as requested by all three referees) -the relevant ALIX experiments need to be repeated with the presence of potentially confounding GST tags (see referees 2, 3) -ALIX oligomerization will have to be confirmed by more suitable methods such as analytical ultracentrifugation, size exclusion chromatography etc -finally, the manuscript would be greatly strengthened by testing ALIX-V binding also to the two main types of poly/oligo-ubiquitin linked via K63 or K48
Major points Bioinformatics: 1) Two runs of the prediction method (starting from the GAT:Ub and VHS:Ub contacs) are described and appear to yield valuable results, since several of the top-200 matches constitute known, non-trivial UBDs (i.e. not closely related to the seed-UBDs). Only selected database hits are shown in tables 1 and 2; the missing results most likely represent known or expected false-positives (structures that are unlikely to recognize ubiquitin). This lack of documentation is unfortunate, since it precludes a real assessment of the method, e.g. through uncovering general trends like preferring helical structures. 2) It is also unfortunate that for the 'true positive' hits (known or expected UBDs), no information on the predicted contact surfaces is given. If I understand the approach correctly, it should not just rank the PDB structures by ubiquitin-binding propensity, but also indicate on what predicted contact residues this score is based on. It should be easy to check to what extent the contact residues of the known UBDs have been predicted correctly. 3) Particularly problematic is the finding of multiple recognition partners for ubiquitin-like modifiers -especially if the authors' explanation is correct that those hits are based on the general fold similarity between ubiquitin and Sumo (in the case of Ubc9), Atg8 (in the case of Atg4A and Atg4B) or the UBX domain (in the case of p97 N-domain). At first glance, the fold-similarity might be an attractive explanation. However, the bioinformatical prediction method is based on the contact residues (of GAT or VHS) while binding to the Ile-44 patch of ubiquitin. However, the ubiquitinlike folds of Sumo, Atg8 and UBX do not contain this Ile-44 hydrophobic surface patch and are recognized completely differently. If the prediction method works ad advertised, it is hard to explain why those non-Ub recognition factors score that high (unless they contain a cryptic ubiquitinbinding surface?). In these cases, it would be of particular importance to know the predicted contact residues of the database hit and to check if those residues are involved in the recognition of the ubiquitin-fold partner.
The method was slightly revised and instead of choosing a-priori defined
The referee is right. We have corrected the text accordingly. Actually, due to the improved scanning procedure and using a new UBD probe (the UBA of E2-25K), these entries have not even been ranked high.
Major points Validation:
Indeed the pulldown assay is not very informative since it is now clear that ALIX-V possesses at least two ubiquitin binding patches (Kopito and co-orkers). Therefore mutation of one Ub binding site (which found by the in silico procedure) can abolish the Ub binding to it self, but has no effect on the other binding site, so it simply shows the affinity of the second Ub binding site. This explains the pulldown results of the ALIX-V mutants. In the light of the referee comments and the low sensitivity of pulldown compared to MST or cross-linking lead us to remove these results from the revised manuscript. Moreover, as you will see we included a new figure (Fig. 6) presenting binding assays to mono-Ub vs. K48/K63 di-Ub and accordingly added explanations to the text. Specifically, we show that WT ALIX-V prefers K63-di-Ub over K48 di-Ub and over mono-Ub. Moreover, mutation at the predicted binding site now clearly shows dramatic lower affinity. As expected, the mutant lacks preferential binding toward mono-Ub or K48/K63di-Ub forms.
Since ALIX-V possesses more than one Ub binding site, mutating the one we found did not abolish mono-Ub binding. Therefor the referee's observation is in general correct. Since we were focused on the Ub binding site derived from the new in silico procedure we did not mutate other Ub binding sites on ALIX-V. The presented mutants therefore show the affinity of mono-Ub to other binding site(s) on ALIX-V. To demonstrate this idea in the revised manuscript, we used di-Ub chains in the binding experiments. A very large difference between mono-Ub and di-Ub is clearly seen when comparing the mutant ALIX-V with the wild type protein signifying the bioinformatic algorithm success to hit one of the Ub binding sites on ALIX-V. In the revised manuscript we added these diUb vs mono-Ub binding experiments (Fig 6 A-C). Then to comparatively quantify the affinity between WT and mutant ALIX-V to Ub we performed cross-linking assays with K63 di-Ub. Fig 6D shows significant difference in the affinity between the WT and the double mutant ALIX-V with reduction of 67%. Similarly Kopito and co-workers found that mutation of this Ub binding site (which the named ERE->3A based on their triple mutant) also decrease the affinity by nearly 80%.

In the light of the new experiments and follows the referee comments about the pulldown assay, we removed the pulldown from the revised manuscript. Although the MST technology is very new it rapidly became very popular and already appear in several dozens of papers some in the highest profile journals. We believe that the discrepancy between the MST and SPR is due to the necessary of immobilization of ALIX-V on the chip. Actually, immobilizing Ub predict to provide lower Kd (higher affinity) value. Similarly, pulldown assays with immobilized Ub presents strong binding to ALIX-V, however, GST:GSH immobilized ALIX-V barely binds Ub. Our data imply that ALIX-V possesses at least two Ub binding sites: one binds the I44 patch and was identified in this manuscript and the other binds different patch on Ub. Thus Ub induces oligomerization by being sandwiched between two ALIX-V molecules. Immobilization of ALIX-V on the SPR chip restricts its ability to oligomerize and therefore significantly decreased the affinity. Kds at range of 2mM were already published in the EMBO J for other UBDs (such as VHS of GAA3, Vps27 and Hrs). In Ub-receptors that contain multiple Ub binding sites we do expect low affinity towards mono-Ub since the affinity to the authentic signal (for example short K63 poly-Ub chains) would be somewhat lower than the product of the binding affinities (Cantor and Schimmel Biophysical Chemistry: Part III).
3) Dimerization of ALIX-V is discussed as one mechanism why immobilized Alix-V does not pull down ubiquitin. However, it is not clear how the claimed ALIX-V:Ub interaction mode, which is totally dependent on the Ile-44 patch, could be helped by dimerizing ALIX -given that the interaction partner is a single ubiquitin-unit, not a chain. The manuscript does not include any data on a possible preference for ubiquitin-chain recognition by ALIX-V. Nowadays, most UBDs are tested for binding to Mono-Ub and at least K48-and K63-linked ubiquitin chains. Strictly speaking, determination of chain specificity is not crucial for the validation of the bioinformatical claims. However, given the mixed results from the validation experiments, data on ubiquitin chain binding could be useful nevertheless. figure (Fig 6) clearly shows this phenomenon. We added explanation for this hypothesis in the results section.
Second site interaction is probably not via the I44 hydrophobic patch. This explains why the new procedure did not find this second site. Moreover, it provides an explanation for our finding that mono-Ub induces oligomerization, since two ALIX-V molecules can simultaneously bind a single Ub molecule through a two different patches on the latter. In the revised manuscript new
As suggested by the referee we performed binding assays with K48/K63 Ub chains. We found in accordance to the recently publish Kopito and co-workers data, that ALIX-V prefers K63 di-Ub over mono-Ub and K48 di-Ub. Moreover, we already showed (Fig 5 in the revised manuscript) that at high mono-Ub concentrations two bands above ALIX-V corresponding to two binding sites of Ub are clearly observed. At the same concentration the Ub-L8E, I44E, V70D triple mutant shows single band above ALIX-V which we believe refers to Ub interaction with the second binding site.
4) Some of the observed problems in mutating away the ubiquitin affinity could be caused by the presence of a 2nd ubiquitin binding site in ALIX-V. This possibility is briefly mentioned in the manuscript but not followed-up on. Is the bioinformatical method capable of predicting secondary binding surfaces? Minor points:
Indeed in parallel to this work Kopito and co-workers found that ALIX-V binds
1) The authors state that most ubiquitin receptors are regulated by auto-ubiquitylation and that some of these processes are E3-independent. Unless the protein of interested is itself an E3, every auto-ubiquitylation must be E3-independent by definition. 2) Why is the MST measurement performed on GST-Alix? As far as I can see, GST is not required for the MST method and could interfere with the affinity. Fig 5A. Unfortunately, due to the lack of such MST system in Israel and given the very limited time for the revision, we could not re-measure the ALIX-V:Ub affinity after removal of the GST affinity tag. We therefore addressed this comment by performing additional binding experiments with free ALIX-V (without GST) and Ub using a different methodology (see Fig 6) .
As suggested by the referee, there is no need of GST in MST measurements. We actually demonstrate binding without GST in
3) The personal communication cited on page 13 was probably by Ron Kopito (rather than Kapito)
We corrected this typographical error.
4) The manuscript does not discuss the evolutionary conservation of the predicted contact residues in ALIX. On the basis of conservation, it should be possible to predict if only human ALIX is predicted to bind ubiquitin or if this property is shared by ALIX proteins from differenc species.
We thank the referee for this comment. We added short section in the results section regarding the evolutionary conservation at the Ub binding site that was found in ALIX-V as well as figure showing the conservation of these sequences (Fig. 4D) Despite the major points of criticism, the data presented make it more likely than not that ALIX-V binds to ubiquitin, that this binding has physiological consequences, and that it uses the predicted interaction surface (possibly in combination with other surfaces). It is just the single, unequivocal proof for a direct binding (as bioinformatically predicted), which is missing.
1. The principle that ubiquitin complexes can be used to predict additional UBDs is reasonable and worth demonstrating. It is not clear however how the current work expands the already existing SiteEngine algorithm. Furthermore, if advancements have been made it is also not clear how the new software will be disseminated and more importantly, additional validation should be performed and comparisons made to currently existing approaches, including the currently available SiteEngine server. Figure 2 is clear from the text, but the figure itself is not obvious and does not contribute much. In addition the mutational analysis for Figure 5A is subtle at best and it is not clear whether the mutations made in Figure 5D compromise the structural integrity of ALIX. This is most likely the case for the ALIX-V triple mutant, and it is not clear whether the more soluble double mutant is properly folded. Overall this analysis does not convincing validate the structural model of Figure 3A . It is also not clear that the authors mean by "It is worth noting that large variability was found in the pulldown assays" (p. 8, top). T681A is not included in Figure 5 , but appears in the functional assay of Figure 7 . Finally, the concern of structural integrity of the ALIX-V double mutant becomes important for Figure 7 , as the authors specifically attribute effects to loss of Ub interaction. Also, ALIX-V mediated inhibition of WT EIAV Gag appears comparable to ΔYPDL-Ub EIAV Gag by the E449A-I450S mutation, which is not how the data is presented in the text. The significant difference seems to be restricted to F676D.
The comparison intended in
We thank the referee for these important comments. We corrected them all. Specifically, the comparison shown in Fig 2 has 3. Figure 4B should be also performed with reducing agent to validate the identification of ALIX~Ub.
If we understand correctly the purpose of this comment, the referee is concerned about the formation of the covalent bond between ALIX-V and Ub. In the ubiquitylation process, the outcome of ubiquitylation indeed results in a covalent bond between the c-terminus of Ub and the substrate. Reducing agent will affect a covalent thiolic bonds between E1~Ub or E2~Ub. However substrate ubiquitylation takes place on lysine residues forming an iso-peptide bond, which could not be opened by the addition of reducing agents. We therefore use a standard SDS-PAGE analysis in which the sample has been diluted and boiled in the presence of a reducing agent (DTT). The reconstituted ubiquitylation system that was used for the ubiquitylation assay has been comprehensively and thoroughly validated in a former study.
4. The conclusion that ubiquitin stabilizes oligomeric ALIX is premature. The amount of oligomerized ALIX in Figure 6B and 6C with Ub present is tiny compared to the momeric species and although there is more oligomer with Ub than without, there is also less monomeric Alix shown in the lane marked -Ub. This section should be complemented with another technique such as analytical ultracentrifugation. In addition, it appears that the experiments of Fig 6 are Kaplan and colleagues use an interesting computational approach here to identify new ubiquitin (Ub) binding domains (UBDs). The protein they focus on is Alix, which had previously been shown to bind ubiquitin-agarose, although those experiments were carried out with complex cell lysates and the interaction might have been indirect.
1. Whilst acknowledging in the discussion that the relevant ligand may well be K63-linked Ub chains, the only measurements provided in this paper are based on monomeric ubiquitin. If ubiquitin binding is promoting oligomerisation, assessing the effect of Ub chains would be highly relevant. Figure 5B . It is disconcerting that the authors report their pulldown experiments as very variable and fail to provide error bars. In addition, they come up with extremely low affinity measurements using SPR, which are clearly at least 2-4 x lower than those reported for other UBD. One key issue with all binding experiments may be the use of GST-tagged proteins given that GST is known to promote parallel dimerisation. Clearly this can grossly confuse the issue in experiments aimed at measuring binding affinities and multimerisation, making some of the experiments hard to interpret (see eg Sims, NSMB 2009).
The pulldown figure presented in the former manuscript version has been performed with proteins without the GST tag. Nevertheless we took the referee's comment into account and removed the figure from the revised manuscript. In addition in the new cross-linking binding experiment of WT and mutant ALIX-V (Fig 6) GST has been removed prior the assays. It worth pointing out that the oligomorezation experiments using MST and cross-linking assays (Fig. 5) were also performed after removal of the GST-tag, emphasizing the importance of the referee comment. We clarify this in the text of the revised manuscript.
4. Figure 6A : The data used to derive the Hill coefficient (which in the abstract is erroneously given in µM), should be presented as a Hill plot. It is hard to see the single data points in the current graphs, but one wonders whether there are in fact enough data points in the critical region to confidently derive a Hill coefficient. 5. The functional data are based on an artificial Ub-cargo, rather than on a wild-type viral protein, and the assay measures the negation of a dominant negative inhibitory effect caused by overexpression of the Alix V-domain. In the end the assay simply measures ubiquitin binding again -but in a different context, rather than providing evidence for a physiological relevance or a requirement for Ub binding in endogenous Alix, which may be achieved by a knockdown and rescue experiment, with a viral gag protein that has not been fused to Ub.
We agree with the reviewer. 6. The oligomerisation data based on crosslinking are very hard to interpret -could this be addressed by gel filtration? And is the protein used in these experiments also GST-tagged? The authors mention a potential second ubiquitin binding site -would that affect the multimerisation assays? Would these not better be conducted with the isolated V-domain?
The referee raised an important point. GST is a dimer and therefore all oligomerization experiments must be performed without GST. We therefore removed the GST-tag using His 6 -TEV protease followed by NTA column to remove the protease and Size exclusion chromatography (SEC) Please excuse the delays associated with the re-evaluation of your manuscript over the holiday period. We have now heard back from the original referees 1 and 3, and I am happy to inform you that both of them consider the manuscript improved and now in principle suitable for publication. Referee 3 only requests some minor text/figure changes, which I would like to ask you to rapidly implement. Please simply send us the revised text and respective figure files per email, and we will upload them into our submission system. After that, we should be able to swiftly proceed with formal acceptance and publication of your study! Thank you again for this contribution to our journal, and congratulations on a successful publication. Please consider us again in the future for your most exciting work! ___________________________________ Referee #1
(Remarks to the Author) The new manuscript version addresses all of my points raised in the initial review in a satisfactory way.
